HomeStock SectorsBioTechShould I Invest In...

Should I Invest In Biotech Stocks?

Biotech, short for biotechnology, is an industry responsible for making life-saving and life-changing drugs. The industry, having made a name for itself with the discovery of insulin, has helped the global population to live longer and healthier lives. 

The sector is a major player in combating epidemics and pandemics – which, because of Covid-19, has made biotech more visible and able to grow through extensive investment.

Through research, clinical trials and manufacturing, companies like Vernal Biosciences are stocking pharmacy shelves with important vaccines and medicines.

It’s possible you’ve never heard of the biotech industry before now and so you may be surprised by how much money it generates. The biotechnology sector is worth hundreds of billions of dollars and is one of the largest industries in the world.

If you’re interested in exploring whether investment in this industry is wise, you’ve come to the right article. Read on to discover more about the industry and find out whether buying stocks is an economically-sound choice.

What Is Biotech?

Biotech is the process of using biological practices to solve health problems. It is a vital industry. The end-goal of the sector is the creation of safe and effective products which can be mass produced, including vaccines, drugs and medicines.

Biopharmaceutical processes are driven by technology, which is used to capture data, conduct research and create products for market.

The biotech industry is one of the largest industries in the world, worth over $1,023.92 billion. In the UK alone, the industry employs 268,000 people across 6,330 businesses – with a turnover of £88.9 billion. Evidence demonstrates that the industry continues to grow each year at speed, making it a viable consideration for personal investment.

Investing In Stocks

Investing in stocks can be a challenging game of luck, with many examples of misfortune and losses. Investing too much of your money in the wrong industry or product can have devastating results, including bankruptcy.

Fortunately, evidence points to the biotech space being a fruitful environment with gains to be made. 

Investing In Biotech Stocks

The biotech industry is enjoying huge growth every year. This is largely a result of large investments, including the £2.8 billion injected in 2020 – a time when other industries were suffering as a result of the Covid-19 pandemic.

On the topic of Covid-19, this major global event has drawn more attention to the biotech industry than any event previously. This extra visibility has generated large investments, while high salaries in the sector are attracting more candidates to roles.

The immense growth of the industry makes investing in biotech stocks a largely economically-sensible decision. There are, of course, risks with all investing – but with the market expected to have a compound annual growth rate of 13.8% from 2022 to 2030, the evidence points to huge rewards for those who invest in biotech.

When To Invest In Biotech Stocks

There’s no better time than now to invest in the biotechnology industry. If growth in the sector happens as predicted, it’s best to get ahead of the curve and invest today. Leaving the decision to invest, while you wait to see how the sector performs, may leave you in a less financially-positive situation – able to generate less income. 

The Bottom Line

The biotechnology industry is one of the largest sectors and Covid-19 has created major growth. While it’s always important to consider your financial position before investing, and understand the risks associated with doing so, buying stocks in biotech is one of the safest investment decisions you could make – based on growth predictions and market value.

Disclaimer

Most Popular

More from Author

June Payrolls Jump, but Other Growth Indicators Paint a Sluggish Picture

June beats consensus on the back of education and health...

Fed Gets Breathing Room as Labor Market Holds Firm

The monthly jobs report hit today (unusually, on a Thursday, due...

How California’s Housing Reforms Could Reshape US Cities Over the Next Decade

Things are moving fast these days. Texans for Reasonable Solutions, among others,...

Week Ahead – RBA, RBNZ Decisions and Fed Minutes Eyed as Trade Deals Awaited

July 9 tariff deadline looms as trade deals remain elusive Fed minutes...

Read Now

June Payrolls Jump, but Other Growth Indicators Paint a Sluggish Picture

June beats consensus on the back of education and health services employment, while private NFP surprises downside. With S&P Global monthly flat over the last six months through May, many key indicators followed by the NBER  Business Cycle Dating Committee (BCDC) are flat or falling...

Fed Gets Breathing Room as Labor Market Holds Firm

The monthly jobs report hit today (unusually, on a Thursday, due to the real and perfectly sensible holiday tomorrow blocking the typical Friday release) and the reaction was immediate. All the equity futures remain strong, but paradoxically, it can sometimes be a spike to the upside that...

How California’s Housing Reforms Could Reshape US Cities Over the Next Decade

Things are moving fast these days. Texans for Reasonable Solutions, among others, has helped push through a number of housing reforms in Texas. Maine has passed a couple of bills that should allow more step-change urban development, as I put it in the “Market Segmentation” post. And California has suddenly...

Week Ahead – RBA, RBNZ Decisions and Fed Minutes Eyed as Trade Deals Awaited

July 9 tariff deadline looms as trade deals remain elusive Fed minutes to be watched after positive jobs report RBA expected to cut but RBNZ to likely stay on hold OPEC+ to probably raise output again UK GDP, Canadian employment and Chinese CPI data also on tap The Race to the Finish...

The Fiscal Treadmill Is Speeding Up and Washington Keeps Jogging

As of 1980, the rolling 10-year and 20-year real GDP growth rates stood at 3.2% per annum and 3.5% per annum, respectively. Owing to a slight boost from the good parts of Reaganomics—sweeping deregulation, tax rate cuts, and sound money, which were partially offset by the long-term ills...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera's Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy SolutionsDistinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera's Scientific Advisory Board.Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.In collaboration...

Risk Assets Extend Gains but Low Volumes Could Skew Monday Open

Yesterday’s market action was driven by consecutive upside surprises in US (147K vs 110K exp) and data (50.8 vs 50.5 exp), fueling another wave of positive sentiment and pushing US equities into yet another frenzied rally. The reaction to the data was progressive but consistent, taking...

Risk-On Sentiment Fades as Tariffs Return to the Spotlight

Dollar surrenders gains posted after robust labour market report Trump celebrates US budget bill approval; scheduled to sign it today Most Fed members feel more comfortable as July rate cut is priced out Oil steadies near $66, gold rally retains momentum Thursday Proved to Be Rather EventfulWhile the US is celebrating...

Oil Prices Set to End the Week With a Modest Gain

prices were on course for a modest weekly gain today, buffeted by both headwinds and tailwinds, including OPEC+ policy, U.S. job numbers, and anticipation of President Trump’s next move on tariffs. At the time of writing, was trading at $68.58 per barrel, with West Texas Intermediate...

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer’s Trial Data – Cognition Therapeutics (NASDAQ:CGTX), InMed Pharmaceuticals (NASDAQ:INM)

Cognition Therapeutics Inc CGTX rose 12.10% to $0.45 during after hours on Thursday, following a surge of 20.82% gain during regular hours. What Happened: The hike in Cognition Therapeutics’ stock price is attributed to the promising results from its Alzheimer’s drug, Zervimesine. The drug achieved a 95% efficacy...

Oil: How Traders Capitalized on Extreme Price Swings

The first half of the year saw significant oil price volatility influenced by U.S. trade policies, OPEC+ production decisions, and geopolitical tensions. Oil prices initially slumped due to new U.S. tariffs and increased OPEC+ output, leading traders to amass short positions. Prices later spiked in June due to Middle...

Gold Prices Slide as Strong NFP Data Undermines Fed Rate Cut Hopes

Strong NFP Data Put Downward Pressure on Gold Yesterday’s US (NFP) data showed that the labour market remains resilient, putting downward pressure on Gold (). In June, companies created more jobs than expected, and the unexpectedly dropped towards 4.1%. The overall report was better than expected, reducing...